GlassScriptPhysician profile
Allison Butler
NPI 1093913212
$5,770.96
in general payments reported to CMS, 2019-2025
29 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $559 · 2021: $851 · 2022: $752 · 2023: $844 · 2024: $1,274 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.20 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,052.50 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,080.43 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $533.96 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $418.83 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $284.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Allergan, INC. | $173.92 | 2019-2021 | |
| Corcept Therapeutics | $120.78 | 2023-2024 | Korlym |
| Glaxosmithkline, LLC. | $120.24 | 2019-2025 | Shingrix, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $100.54 | 2020-2024 | Gardasil, Gardasil 9, Vaxelis |
| Inspire Medical Systems, INC. | $100.04 | 2024 | Inspire |
| Pfizer INC. | $98.25 | 2023-2025 | |
| Boston Scientific Corporation | $85.85 | 2021 | |
| Abbott Laboratories | $72.68 | 2023-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $71.43 | 2021-2022 | |
| Edwards Lifesciences Corporation | $68.00 | 2025 | Sapien 3 Ultra Resilia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $58.86 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $51.57 | 2020-2025 | Strensiq |
| Nestle Healthcare Nutrition INC. | $36.16 | 2022 | |
| Sumitomo Pharma America, INC. | $35.79 | 2025 | Gemtesa |
| Amgen INC. | $32.11 | 2020-2023 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $22.66 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $22.37 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.61 | 2020 | |
| Exact Sciences Corporation | $20.54 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $20.54 | 2019 | |
| Medtronic, INC. | $17.19 | 2024 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $16.53 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.